Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SoftOx Solutions AS ( (DE:6FV) ) has issued an announcement.
SoftOx Solutions AS has published its Annual Report for 2024, with the Board of Directors approving the financial statements in line with Norwegian accounting standards. This announcement underscores the company’s commitment to transparency and adherence to regulatory requirements, potentially bolstering stakeholder confidence and reinforcing its position in the pharmaceutical industry.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company focuses on developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi, leveraging extensive research and development in collaboration with leading Nordic research institutes.
YTD Price Performance: 542.86%
Average Trading Volume: 57,630,965
Current Market Cap: NOK168M
For a thorough assessment of 6FV stock, go to TipRanks’ Stock Analysis page.